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age annual costs were estimated by health service and patient. Costs were adjusted 
for inflation and expressed in 2014 US dollars. RESULTS: The prevalence of BC was 
247.72 per 100,000 members, the average age was 58.86 years (SD 13.05 years), cit-
ies with higher concentrations of patients were Bogotá (35.08%), Medellin (10.65%), 
and Barranquilla (9.67%). The average annual cost of health care for 1314 patients 
was $ 5,709,078.15, given mainly by chemotherapy with 31.36%, followed by drugs 
(27.34%), radiotherapy (7.48%), hospital surgery (6.26%), diagnostic and therapeu-
tic procedures (3.55 %) and hospitalization (3.22%). The average annual cost per 
patient was $ 8350.95 (2010), $ 7798.91 (2011), $ 6719.66 (2012), $ 5910.49 (2013) and 
$ 5214.47 (2014). CONCLUSIONS: The average annual cost per patient with BC in 
an insured population in Colombia is equivalent to the annual premium per capita 
of 17 patients by 2014. I an average decrease in cost per patient of 38% was found 
during the follow.
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OBJECTIVES: Simple contact dermatitis (CD) and pressure ulcers (PU) of immobi-
lized patients with urinary is an important and not enough explored clinical and 
economic problem in hospitals and social care organizations. METHODS: An obser-
vational clinical and economic study of a typical practice of CD and PU. In the study 
taken forms of 85 patients, analyzed in 7 critical points each. Patients had a higher 
risk of CD and PU. The average age - 76 ± 5,6 years. RESULTS: Patients without CD 
and PU - 25 persons (29.8%), with PU 50 persons (58.8%), with CD 35 persons (41.1%). 
In 19 patients (22.4%) had and PU and CD in various critical areas. CD was marked in 
75 points (12.6%), PU 1-2st - 93 points (15.6%), PU 3-4st - 8 points (1.3%). Total costs 
in rubles (1$ US = 34 ₷) for 1 patient in the group without the CD and PU were 12895, 
drugs -325, on care products -391, for services -12179. In the group “PU 1-2st” total 
costs 13546, on drugs -267, at the expense of care -769, for services -12510. In the 
group “PU 3-4st “ total costs 25290, on drugs –161, on care products -4356, for services 
- 20 773. In the group of “KD” total costs 16027, on drugs -146, on care products 1349, 
for services – 14532. CONCLUSIONS: The frequency of PU is 58.8%, KD - 41.1%, KD 
and PU - 22.4%. Without CD and PU - 29.8%. Total costs are the biggest in group of 
patients with high degrees of PU, due to the high cost of services and care products. 
Drug costs are not high. A high cost in the CD group is associated with services and 
care. The data will be used to construct a Markov model.
PHS43
eConomiC burden of ColoreCtal CanCer in Vietnam: from 
HealtHCare PayerS’ PerSPeCtiVe
Phan T., Hoang B., Nguyen T.T.
University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
OBJECTIVES: Colorectal cancer (CRC) is considered as the third common cancer 
among men and the second common cancer among women worldwide. In Vietnam, 
colorectal cancer is the fifth common cause of cancer - related incidence. In many 
countries, economic burden of colorectal cancer has been investigated logically. 
However, there have not had any research about this in Vietnam. This research was 
conducted to provide more detail information to help the decision-makers find out 
the most appropriated policies to control the disease. METHODS: The economic bur-
den of CRC in Vietnam was evaluated by the following formula: C = ∑Pi x COIi.; in 
which, C: economic burden of CRC in Vietnam, Pi: number of patients in stage i of CRC 
in Vietnam, COIi: cost of CRC in stage i. RESULTS: The 5-year prevalence of CRC is 27.3 
per 100,000. The economic burden of CRC of the whole society was estimated about 
14,268.3 billion VND. The values fluctuated sharply from stage I to stage IV, accounted 
for 6.9 billion VND; 5,731.2 billion VND; 3,564.5 billion VND and 4,965.7 billion VND, 
respectively. As lots of patients were diagnosed at stage II (about 38%), the economic 
burden of this stage was predominant (40%) compared to the others. Furthermore, 
in all stages except stage I, the economic burden related to medicine was much more 
higher than that of medical services. CONCLUSIONS: The high economic burden 
of CRC should be considered to conduct relevant healthcare policies, especially for 
patients in advanced stages. Key word: economic burden, colorectal cancer.
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OBJECTIVES: In 2013 December, PAHO confirmed the local circulation of chikungu-
nya virus (CHKV) in the region. In 2014 September Colombia reported the first local 
CHKV case in the Bolívar, and started an outbreak within a susceptible population. 
The objective of this analysis is to estimate the medical care cost of children patients 
with suspect of CHKV attended at a reference pediatric Hospital in Cartagena-
Bolivar, at the start of the CHKV local transmission in Colombia. METHODS: A ret-
rospective bottom-up cost analysis was designed. We selected randomized sample 
of clinical records from children patients with CHKV clinically suspected during 
September – November 2014 at the Hospital “Napoleón Franco Pareja” in Cartagena 
city, Colombia. A costing data collection instrument was designed a piloted to col-
lect the information about the frequency of use activities and supplies by patient. 
Administrative and cost data by patient and activity were obtained from the 
Hospital. Costing items included: consults, hospitalization bed-day, supplies, drugs, 
and diagnosis and therapeutic procedures. Total cost per cost item and patient were 
estimated and average cost per patient reported. Costs were expressed in 2014 USD 
with an Exchange rate of 2392.46 COP per American dollar. RESULTS: A sample of 
conducted based on the perspective of healthcare payers; therefore, only medical 
direct cost was evaluated. The cost of medical service and drugs were retrieved 
from the price-list of relevant medical services and drugs, registered by Ministry of 
Health in Vietnam 2012. RESULTS: The average direct cost of CRC for one patient 
accounted for nearly 756.83 million VND per year. Cost for one patient increased 
with the increasing of disease severity and accounted for 1.875 million VND; 800 mil-
lion VND; 822 million VND and 1,351 million VND in stage I, II, III, IV, respectively. In 
the structure of cost, with the increase in severity of disease, the percentage of drug 
cost increased and the percentage of medical services decreased. CONCLUSIONS: 
The cost of CRC treatment increased following the increase of disease severity. The 
huge economic impact of CRC should be controlled and considered to conduct the 
proper healthcare policies.
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OBJECTIVES: To examine the association of direct medical costs with clinical and 
health characteristics in visually impaired individuals in Singapore. METHODS: 
We prospectively recruited 500 visually impaired individuals due to cataract, glau-
coma, diabetic retinopathy (DR), or age-related macular degeneration (AMD) from 
Singapore National Eye Centre. In face-to-face interviews, vision function and health 
status of the individuals were assessed using the 14-item Visual Functioning (VF-14) 
and EQ-5D questionnaires, respectively. Severity of visual impairment (VI) and direct 
medical costs were determined using clinical and billing data, respectively, in the 
study center. Annual medical costs per capita were estimated and compared for 
individuals with different eye diseases and in different levels of VI, vision function, 
and health status using generalized linear models. RESULTS: The mean (standard 
deviation [SD)] age of participants was 71.6 (9.8) years old. The proportion of male 
was 47.6% and the mean (SD) presenting visual acuity was 0.49 (0.31). The annual 
medical costs per capita were S$6.8K. After adjusting for socio-demographics, the 
annual medical costs differed in individuals with different eye diseases (AMD 
higher than cataract by S$13.1K, glaucoma by S$9.2K, and DR by S$12.4K), VI sever-
ity (between mild/moderate and severe VI: S$8.8K), vision function (between absence 
and presence of problems: S$3.7K), and health status (between absence and pres-
ence of problems: S$1.3K). CONCLUSIONS: Direct medical costs are highest in AMD 
individuals and are associated with clinical measure and vision function in visually 
impaired individuals in Singapore.
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OBJECTIVES: Vaccination against influenza, pneumococcal disease and herpes zos-
ter are recommended for the elderly, who have high morbidity and mortality rates 
due to these three diseases. Many studies investigated the clinical burden by each 
vaccine-preventable disease; however, empirical data on the full economic burden 
of adult vaccine-preventable diseases is scarce. This study examines the healthcare 
resource utilization and medical expenditures of elderly with vaccine-preventable 
diseases in Taiwan. METHODS: We included 104,273 beneficiaries aged 65 years or 
older under the Taiwan’s National Health Insurance program in 2010. Patients with 
vaccine-preventable diseases were defined as those who had at least one diagno-
sis of flu, pneumococcal disease, or herpes zoster. Outcomes of interest include 
healthcare resource utilization (inpatient, outpatient, and emergency department 
(ED) visits) and associated medical expenditures. RESULTS: In 2010, there were 
6.77%, 3.18% and 1.88% of elderly population had been diagnosed and received 
ambulatory care for pneumonia, flu and herpes zoster, respectively. However, on 
average, patients with pneumonia, flu, herpes zoster visited the doctor’s office 36.9, 
37.3, 38.5 times (without those diseases: 26.7 times), respectively. The healthcare 
resource utilization from patients with vaccine-preventable diseases attributed to 
large proportion of medical expenditures. Among annual medical expenditures 
for the elderly (US$0.2 billion), 13.08% of expenditures cost from pneumonia care, 
3.10% from flu and 2.53% from herpes zoster. Average cost per patient were US$3.6 
thousand, US$1.8 thousand and US$ 2.5 thousand for pneumonia, flu and herpes 
zoster, respectively. CONCLUSIONS: This study demonstrates significant burden of 
healthcare utilization caused by older people with vaccine-preventable diseases. In 
addition, different management strategies may be warranted for different vaccine-
preventable diseases since the differences of patient characteristics as suggested 
by our study.
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Breast cancer (BC) is one of leading causes of death in women and is also considered 
a catastrophic illness associated with a large financial burden on the health system 
with incremental trend.OBJECTIVES: To estimate the direct costs associated with 
the health care of patients with BC affiliated with a health manteinance organiza-
tion (HMO) in Colombia during the period 2010-2014. METHODS: A retrospective 
cross-sectional study was conducted in a cohort of 1314 patients with BC affiliated 
with a HMO in Colombia and distributed in 16 cities of the country, in the period 
2010 to 2014. Demographic characteristics of the cohort are described and the aver-
